1. Skip to Menu
  2. Skip to Content
  3. Skip to Footer

Sexual Enhancement - KDM-1101 (“X-Excite”)

Sexual Enhancement - KDM-1101 (“X-Excite”)

Erectile dysfunction is a physical condition that affects 10% of men worldwide. The current treatment is the use of drugs that prevent the enzyme 5-phosphodiesterase. Most notable products of this class are Sildenafil, Tadalafil, and Vardenafil, ...

Read more...

Cardiovascular - KDM-1102

Cardiovascular - KDM-1102

With over 190 million prescription a year and over $2 billion revenue, beta-blockers, the family of Propranolol group of drugs have been the most effective tools for various forms of cardiovascular diseases most importantly hypertension and angina. These drugs also being used ...

Read more...

Osteoporosis - KDM-1103

Osteoporosis - KDM-1103

Over one billion people suffer from osteoporosis worldwide; most are seen in female population. Due to hormonal changes, post labor and post menopause, bone density is reduced which leads to pain, suffering and occasional bone breaking. Current family of bisphosphonate drugs are used for osteoporosis, as well as control of certain forms of bone growth  ... Read more...

Migraine - KDM-1104

Migraine - KDM-1104


Migraine is a serious neurological disorder characterized by recurrent headaches, varying in severity and frequency. Accounting for the loss of over 100 million working days in the US alone, the economic cost and social impact of migraine is significant. Treatmen... Read more...

Previous
Next
  • Sexual Enhancement - KDM-1101 (“X-Excite”)

    Sexual Enhancement - KDM-1101 (“X-Exci

  • Cardiovascular - KDM-1102

    Cardiovascular - KDM-1102

  • Osteoporosis - KDM-1103

    Osteoporosis - KDM-1103

  • Migraine - KDM-1104

    Migraine - KDM-1104

Insight From Dr. Salari

"Major pharmaceutical companie are facing a steep revenue decline because of looming patent expirations and lack of innovation for new drugs. Specialty pharmas and biotech companies are becoming highly desirable due to their pipeline of new drugs and solid innovations.

I believe a large number of young companies such as ours are to be the target of acquisition by these large multinational pharmaceutical companies. This shall reward our stockholders handsomely when the acquisition are made."


Hassan Salari, Ph.D.
Chairman & CEO Dr.